

FILE 'REGISTRY' ENTERED AT 12:39:48 ON 26 JAN 2008

L1 STRUCTURE UPLOADED
L2 2 S L1
L3 23 S L1 FUL

FILE 'CAPLUS, USPATFULL, USPATOLD, USPAT2' ENTERED AT 12:42:58 ON 26 JAN 2008

L4 27 S L3
L5 6 S L2
L6 27 S L5 OR L4
L7 11623 S COPD OR CHRONIC (W) OBSTRUCTIVE (W) LUNG
L8 1 S L7 AND L6

FILE 'CAPLUS' ENTERED AT 12:56:46 ON 26 JAN 2008

E COPD/CT
E CHRONIC OBSTRUCTIVE LUNF DISEASE/CT
E E17+ALL
L9 5959 S E26
L10 1 S L9 AND L6
E E17+ALL

FILE 'CAPLUS, USPATFULL, USPATOLD, USPAT2' ENTERED AT 13:53:43 ON 26 JAN 2008

SAV L5 C10565828/A

FILE 'HOME' ENTERED AT 13:53:56 ON 26 JAN 2008

FILE 'CAPLUS' ENTERED AT 14:11:38 ON 26 JAN 2008

=> S L3
L11 14 L3

=> E EMPHYSEMA/CYT
'CYT' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'CAPLUS'
The indicated field code is not available for EXPAND in this
file. To see a list of valid EXPAND field codes, enter HELP
SFIELDS at an arrow prompt (=>).

=> E EMPHYSEMA/CT

E#	FREQUENCY	AT	TERM
--	-----	--	----
E89	1	9	EMPHOROPSIS MISERABILIS/CT
E90	0	1	EMPHYLLOCALYX/CT
E91	2795	12 -->	EMPHYSEMA/CT
E92	0	2	EMPHYSEMA (L) PULMONARY/CT
E93	51	2	EMPHYSEMA (PULMONARY)/CT
E94	0	9	EMPHYTUS/CT
E95	1	9	EMPHYTUS CINCTUS/CT
E96	0	9	EMPIDADELPHA/CT
E97	1	9	EMPIDADELPHA SOBRINA/CT
E98	9	66	EMPIDIDAE/CT
E99	2	7	EMPIDOIDEA/CT
E100	0	1	EMPIDOKYREA/CT

=> E E91/+ALL
'+ALL' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'CAPLUS'
The indicated field code is not available for EXPAND in this
file. To see a list of valid EXPAND field codes, enter HELP
SFIELDS at an arrow prompt (=>).

```
=> E E91+ALL
E101      37387   BT4   Disease, animal/CT
E102           0   BT3   Diseases, by body part (non-CA heading)/CT
E103      645     BT2   Organ, animal, disease/CT
E104      37387   BT3   Disease, animal/CT
E105      11342   BT2   Respiratory system, disease/CT
E106      27977   BT1   Lung, disease/CT
E107      2795    -->   Emphysema/CT
                        HNTE Valid heading during volume 1 (1907) to
                        present.
E108                        OLD   Emphysema (L) pulmonary/CT
E109      51      OLD   Emphysema (pulmonary)/CT
E110                        UF    Chronic emphysema/CT
E111                        UF    Chronic obstructive emphysema/CT
E112                        UF    Pulmonary emphysema/CT
***** END *****
```

```
=> S E91
L12      2795 EMPHYSEMA/CT
```

```
=> S L11 AND L12
L13      1 L11 AND L12
```

```
=> D HIS
```

(FILE 'HOME' ENTERED AT 12:39:35 ON 26 JAN 2008)

FILE 'REGISTRY' ENTERED AT 12:39:48 ON 26 JAN 2008

```
L1      STRUCTURE UPLOADED
L2      2 S L1
L3      23 S L1 FUL
```

FILE 'CAPLUS, USPATFULL, USPATOLD, USPAT2' ENTERED AT 12:42:58 ON 26 JAN 2008

```
L4      27 S L3
L5      6 S L2
L6      27 S L5 OR L4
L7      11623 S COPD OR CHRONIC (W)  OBSTRUCTIVE (W)  LUNG
L8      1 S L7 AND L6
```

FILE 'CAPLUS' ENTERED AT 12:56:46 ON 26 JAN 2008

```
      E COPD/CT
      E CHRONIC OBSTRUCTIVE LUNF DISEASE/CT
      E E17+ALL
L9      5959 S E26
L10     1 S L9 AND L6
      E E17+ALL
```

FILE 'CAPLUS, USPATFULL, USPATOLD, USPAT2' ENTERED AT 13:53:43 ON 26 JAN 2008

SAV L5 C10565828/A

FILE 'HOME' ENTERED AT 13:53:56 ON 26 JAN 2008

FILE 'CAPLUS' ENTERED AT 14:11:38 ON 26 JAN 2008

```
L11     14 S L3
      E EMPHYSEMA+ALL/CT
      E EMPHYSEMA+ALL/CT
      E EMPHYSEMA+ALL/CT
      E EMPHYSEMA+ALL/CT
```

E EMPHYSEMA+ALL/CT
E EMPHYSEMA/CT
E E91+ALL


L12 2795 S E91
L13 1 S L11 AND L12

=> S L13 OR L10 OR L8
L14 2 L13 OR L10 OR L8

=> D HIS IABS IBIB HITSTR 1-2
'IABS' IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY HISTORY".

=> D IABS IBIB KWIC HITSTR 1-2

L14 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
GRAPHIC IMAGE:



ABSTRACT:

The invention relates to an inhalant composition for treatment of respiratory disease, characterized by containing 7-aminoquinolinone derivative I (R1 = H, alkyl; R2, R3 = H, acyl, alkyl, and alkenyl; and R4, R5 = H, acyl, alkyl, alkenyl, aralkyl) or a physiol. acceptable salt of the derivative as an active component. The effect of inhalation of a compound I (R1 = methyl; R2 = octyl; R3, R4 = H, R5 = 3,5-dimethoxy-4-hydroxycinnamoyl) in asthma model guinea pigs was examined

ACCESSION NUMBER: 2005:405060 CAPLUS <<LOGINID::20080126>>
DOCUMENT NUMBER: 142:435822
TITLE: Inhalant compositions containing 7-aminoquinolinone derivatives
INVENTOR(S): Takagaki, Shuji; Kimura, Nobuyuki; Aoki, Yasuo; Ishihara, Mitsuteru
PATENT ASSIGNEE(S): Dainippon Ink and Chemicals, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005119976	A	20050512	JP 2003-353544	20031014
PRIORITY APPLN. INFO.:			JP 2003-353544	20031014
OTHER SOURCE(S):	MARPAT	142:435822		
IT Allergy inhibitors				
Antiasthmatics				
Asthma				

Emphysema

Pneumonia

Respiratory system, disease

(inhalant compns. containing 7-aminoquinolinone derivs. for treatment of respiratory disease)

IT 194037-05-3 194037-25-7 194037-30-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhalant compns. containing 7-aminoquinolinone derivs. for treatment of respiratory disease)


IT 194037-25-7 194037-30-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhalant compns. containing 7-aminoquinolinone derivs. for treatment of respiratory disease)


RN 194037-25-7 CAPLUS

CN 2-Propenamide, N-[1,2-dihydro-4-hydroxy-1-methyl-3-(octyloxy)-2-oxo-7-quinolinyl]-3-(4-hydroxy-3,5-dimethoxyphenyl)- (CA INDEX NAME)



RN 194037-30-4 CAPLUS

CN 2(1H)-Quinolinone, 4-hydroxy-1-methyl-3-(octyloxy)-7-(2-propenylamino)-(9CI) (CA INDEX NAME)



L14 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ABSTRACT:

A therapeutic agent for chronic obstructive pulmonary diseases which contains as an active ingredient at least either of a 7-aminoquinolinone derivative represented by the general formula (I) (wherein R1 is hydrogen or alkyl; R2 and R3 each is a member selected among hydrogen, acyl, alkyl, and alkenyl; and R4 and R5 each is a member selected among hydrogen, acyl, alkyl, alkenyl, and aralkyl) or a physiol. acceptable salt of the derivative

ACCESSION NUMBER: 2005:120886 CAPLUS <<LOGINID::20080126>>

DOCUMENT NUMBER: 142:191276

TITLE: Therapeutic agent for chronic obstructive pulmonary disease and method of treatment for chronic obstructive pulmonary disease with the same

INVENTOR(S): Takagaki, Hidetsugu; Aoki, Yasuo; Ishiwara, Mitsuteru; Mizutani, Nobuaki

PATENT ASSIGNEE(S): Dainippon Ink and Chemicals, Inc., Japan

SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012251	A1	20050210	WO 2004-JP11013	20040727
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2005060365	A	20050310	JP 2004-72488	20040315
AU 2004261527	A1	20050210	AU 2004-261527	20040727
CA 2533919	A1	20050210	CA 2004-2533919	20040727
EP 1650191	A1	20060426	EP 2004-771118	20040727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1829693	A	20060906	CN 2004-80021713	20040727
US 2006235045	A1	20061019	US 2006-565828	20060125
PRIORITY APPLN. INFO.:			JP 2003-203699	A 20030730
			WO 2004-JP11013	W 20040727

IT Lung, disease

(chronic obstructive pulmonary disease; 7-aminoquinolinone derivs. as therapeutic agents for chronic obstructive pulmonary disease and method of treatment for chronic obstructive pulmonary disease with the same)

IT 194036-90-3 194037-03-1 194037-05-3 194037-06-4
 194037-20-2 194037-25-7 194037-27-9 194037-33-7
 835905-51-6 835905-52-7 835905-53-8 835905-54-9 835905-55-0
 835905-56-1 835905-57-2 835905-58-3 835905-59-4 835905-60-7
 835905-61-8 835905-62-9 835905-63-0 835905-64-1
 835905-65-2 835905-66-3 835905-67-4 835905-68-5 835905-69-6
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (7-aminoquinolinone derivs. as therapeutic agents for chronic obstructive pulmonary disease and method of treatment for chronic obstructive pulmonary disease with the same)


IT 194037-06-4 194037-25-7 194037-33-7
835905-62-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (7-aminoquinolinone derivs. as therapeutic agents for chronic

obstructive pulmonary disease and method of treatment for chronic
obstructive pulmonary disease with the same)


RN 194037-06-4 CAPLUS

CN 2(1H)-Quinolinone, 7-amino-4-hydroxy-1-methyl-3-(octyloxy)- (CA INDEX
NAME)




RN 194037-25-7 CAPLUS

CN 2-Propenamide, N-[1,2-dihydro-4-hydroxy-1-methyl-3-(octyloxy)-2-oxo-7-
quinolinyl]-3-(4-hydroxy-3,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 194037-33-7 CAPLUS

CN Benzamide, N-[1,2-dihydro-4-hydroxy-1-methyl-3-(octyloxy)-2-oxo-7-
quinolinyl]- (CA INDEX NAME)



RN 835905-62-9 CAPLUS

CN 2(1H)-Quinolinone, 4-hydroxy-1-methyl-7-(octylamino)-3-(octyloxy)- (CA
INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> D HIS

(FILE 'HOME' ENTERED AT 12:39:35 ON 26 JAN 2008)

FILE 'REGISTRY' ENTERED AT 12:39:48 ON 26 JAN 2008

L1 STRUCTURE UPLOADED
L2 2 S L1
L3 23 S L1 FUL

FILE 'CAPLUS, USPATFULL, USPATOLD, USPAT2' ENTERED AT 12:42:58 ON 26 JAN 2008

L4 27 S L3
L5 6 S L2
L6 27 S L5 OR L4
L7 11623 S COPD OR CHRONIC (W) OBSTRUCTIVE (W) LUNG
L8 1 S L7 AND L6

FILE 'CAPLUS' ENTERED AT 12:56:46 ON 26 JAN 2008

E COPD/CT
E CHRONIC OBSTRUCTIVE LUNF DISEASE/CT
E E17+ALL
L9 5959 S E26
L10 1 S L9 AND L6
E E17+ALL

FILE 'CAPLUS, USPATFULL, USPATOLD, USPAT2' ENTERED AT 13:53:43 ON 26 JAN 2008

SAV L5 C10565828/A

FILE 'HOME' ENTERED AT 13:53:56 ON 26 JAN 2008

FILE 'CAPLUS' ENTERED AT 14:11:38 ON 26 JAN 2008

L11 14 S L3
E EMPHYSEMA+ALL/CT
E EMPHYSEMA+ALL/CT
E EMPHYSEMA+ALL/CT
E EMPHYSEMA+ALL/CT
E EMPHYSEMA+ALL/CT
E EMPHYSEMA/CT
E E91+ALL
L12 2795 S E91
L13 1 S L11 AND L12
L14 2 S L13 OR L10 OR L8

=> SAV ALL S10565828A/L

=> SAV L14 C10565828B/A

=> S (LUNG OR PULMONARY) AND L11

209066 LUNG

45755 LUNGS

224086 LUNG

(LUNG OR LUNGS)

98466 PULMONARY

2 PULMONARIES

98466 PULMONARY

(PULMONARY OR PULMONARIES)

L15 3 (LUNG OR PULMONARY) AND L11

=> S L15 NOT L14

L16 2 L15 NOT L14

=> D IABS IBIB KWIC HITSTR 1-2

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ABSTRACT:

TA-270 is a novel compound that demonstrates 5-lipoxygenase(LO) inhibition and anti-oxidative action against ONOO- etc. TA-270 was designed on the basis of the ascorbic acid and aspirin, and added with sinapinic acid (an active ingredient of SAIBOKUTOU). Here, we investigated the effects of TA-270 on inflammatory airway diseases using exptl. guinea pig models. In a pre-clin. study, TA-270 strongly improved biphasic asthmatic responses and hyperresponsiveness in allergic asthma models, hyperresponsiveness induced by ozone inhalation in non-allergic models and also biphasic nasal blockages in allergic rhinitis models. The inhibitory effect of TA-270 against the hyperresponsiveness in allergic models was remarkably stronger than that of a cysteinyl leukotriene antagonist, suggesting that the anti-oxidative action rather than 5-LO inhibitory effect contributes to the inhibitory effect of TA-270. It is recently reported that a potent oxidant ONOO- generated from nitric oxide and O2- is involved in the development of respiratory diseases. And our study showed that TA-270 inhibited hyperresponsiveness induced by ONOO- in guinea pigs. These results suggest that the anti-oxidative action of TA-270 is involved in the improvement of airway inflammation. In conclusion, TA-270 is considered to improve airway inflammation through its mechanism of 5-LO inhibitory and anti-oxidative effect, and is expected clin. to demonstrate improvement in airway inflammation including asthma and chronic obstructive ***pulmonary*** disease, and allergic rhinitis.

ACCESSION NUMBER: 2006:42159 CAPLUS <<LOGINID::20080126>>

DOCUMENT NUMBER: 144:246944

TITLE: Effect of a novel quinolinone derivative, TA-270, on inflammatory airway diseases

AUTHOR(S): Mizutani, Nobuaki; Ishiwara, Mitsuteru; Suetake, Kazumi; Aoki, Yasuo; Takagaki, Hidetsugu

CORPORATE SOURCE: Dainippon Ink and Chemicals, Incorporated Central Research Laboratories, Japan

SOURCE: Ensho, Saisei (2005), 25(6), 512-516

CODEN: ENSHCC; ISSN: 1346-8022

PUBLISHER: Nippon Ensho-Saisei Igakkai

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB . . . 5-LO inhibitory and anti-oxidative effect, and is expected clin. to demonstrate improvement in airway inflammation including asthma and chronic obstructive pulmonary disease, and allergic rhinitis.

IT 194037-25-7, TA-270

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(effect of novel quinolinone derivative, TA-270, on inflammatory airway
diseases)


IT 194037-25-7, TA-270

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(effect of novel quinolinone derivative, TA-270, on inflammatory airway
diseases)

RN 194037-25-7 CAPLUS

CN 2-Propenamide, N-[1,2-dihydro-4-hydroxy-1-methyl-3-(octyloxy)-2-oxo-7-
quinolinyl]-3-(4-hydroxy-3,5-dimethoxyphenyl)- (CA INDEX NAME)



L16 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ABSTRACT:

TA-270 (4-hydroxy-1-methyl-3-octyloxy-7-sinapinoylamino-2(1H)-quinolinone), a novel quinolinone derivative, was designed as an antioxidant to scavenge reactive oxygen species. Here, we investigated the effects of TA-270, in comparison with several antiasthmatic drugs, on asthmatic responses as induced by ovalbumin in sensitized guinea pigs. When orally administered 1 h before and 3 h after the antigen challenge, TA-270 at 10 mg/kg and higher doses significantly inhibited both immediate and late responses in airway resistance induced by the antigen. The inhibitory effects were comparable to or superior, at least under the present exptl. conditions, to those of several clin. used antiasthmatic drugs. Furthermore, TA-270, in a dose-dependent manner, reduced accumulation of pulmonary inflammatory cells, especially eosinophils, and significantly reversed the airway hyperresponsiveness to acetylcholine 24 h after the antigen challenge. These results suggest that TA-270 may be of therapeutic use for bronchial asthma.

ACCESSION NUMBER: 2000:854267 CAPLUS <<LOGINID::20080126>>
DOCUMENT NUMBER: 134:202566
TITLE: Inhibitory effect of a novel quinolinone derivative,
TA-270, on asthmatic inflammatory responses in
sensitized guinea pigs
AUTHOR(S): Aoki, Y.; Ishiware, M.; Koda, A.; Takagaki, H.
CORPORATE SOURCE: Central Research Laboratories, Dainippon Ink and
Chemicals, Inc., Sakura, Chiba, 285-8668, Japan
SOURCE: European Journal of Pharmacology (2000), 409(3),
325-330
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB . . . present exptl. conditions, to those of several clin. used
antiasthmatic drugs. Furthermore, TA-270, in a dose-dependent manner,

reduced accumulation of pulmonary inflammatory cells, especially eosinophils, and significantly reversed the airway hyperresponsiveness to acetylcholine 24 h after the antigen challenge. These results. . .

IT 194037-25-7, TA 270

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibitory effect of a novel quinolinone derivative, TA-270, on asthmatic inflammatory responses in sensitized guinea pigs)

IT 194037-25-7, TA 270

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibitory effect of a novel quinolinone derivative, TA-270, on asthmatic inflammatory responses in sensitized guinea pigs)

RN 194037-25-7 CAPLUS

CN 2-Propenamide, N-[1,2-dihydro-4-hydroxy-1-methyl-3-(octyloxy)-2-oxo-7-quinolinyl]-3-(4-hydroxy-3,5-dimethoxyphenyl)- (CA INDEX NAME)

